<DOC>
	<DOCNO>NCT01287845</DOCNO>
	<brief_summary>PET/CT image study evaluation safety tolerability diagnostic performance BAY1075553 patient prostate cancer healthy volunteer</brief_summary>
	<brief_title>PET/CT ( Positron Emission Tomography/Computed Tomography ) Imaging Safety Tolerability Diagnostic Performance BAY1075553 Patients With Prostate Cancer Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Part 1 : Healthy volunteer Males ≥ 40 year age Part 2 : Prostate cancer patient Males ≥ 18 year age Serum PSA ( ProstateSpecific Antigen ) value normal . Patients MRI and/or positive [ 11C ] [ 18F ] choline PET/CT primary diagnosis ( Note : MRI [ 11C ] [ 18F ] choline PET/CT optional primary prostate cancer patient ) recurrence detection prostate cancer primary cancer disease ( adenocarcinoma ) histologically confirm Patients primary prostate cancer schedule prostatectomy In patient primary prostate cancer , histopathological evaluation show adenocarcinoma Gleason score 3 + 3 high least two biopsy location prostate Patients advance primary recurrent prostate cancer high likelihood display lymph node metastasis , ideally schedule explorative pelvic lymphadenectomy , preferably include Part 3 : Prostate cancer patient The criterion eligibility part 3 identical one part 2 . Except long preference mandatory enrol patient presumably high likelihood metastatic disease , especially lymph node metastasis . Concurrent severe and/or uncontrolled and/or unstable medical disease prostate cancer ( e.g . poorly control diabetes , congestive heart failure , myocardial infarction within 12 month prior plan injection BAY1075553 , unstable uncontrolled hypertension , chronic renal hepatic disease , severe pulmonary disease ) could compromise participation study Acute renal insufficiency intensity , either due hepatorenal syndrome occur perioperative liver transplantation period Active inflammatory bowel disease within last 6 month Acute prostatitis require medical treatment within last 6 month A nonurologic bacterial infection require active treatment antibiotic within 3 month Active malignancy ( except basal cell squamous cell skin cancer ) within last 2 year Patients primary prostate cancer : androgen ablation within 3 month plan treatment Subject fulfil criterion opinion investigator preclude participation scientific reason , reason compliance , reason subject 's safety</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Diagnostic Imaging</keyword>
	<keyword>PET ( Positron Emission Tomography ) -tracer</keyword>
	<keyword>PET-diagnosis</keyword>
</DOC>